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Virulent  strains  of  Rhodococcus  equi  have  a large  plasmid  of  80–90  kb,  which  encodes  several  virulence-
associated  proteins  (Vap),  including  VapA,  a lipoprotein  highly  associated  with  disease.  We  have
previously  demonstrated  that  oral  immunisation  with  attenuated  Salmonella  enterica  Typhimurium  strain
expressing  the antigen  VapA  (STM  VapA+)  induces  speciﬁc  and  long-term  humoral  and  cellular  immu-
nity against  R. equi.  It  was  shown  that  VapA  activates  Toll-like  receptor  2  (TLR2)  on  macrophages  by
establishing  an  interaction  that  ultimately  favours  immunity  against  R.  equi  infection.  The  purpose  of
this study  was to  evaluate  the  immune  response  triggered  by nasal  immunisation  with  STM  VapA+  and
to determine  whether  TLR2  supports  the  vaccine  effect.  We  developed  an  optimised  protocol  for  a  single
nasal  immunisation  that  conferred  protection  against  R. equi  infection  in  mice, which  was  manifested
by  efﬁcient  R. equi  clearance  in  challenged  animals.  Nasal  vaccination  with  STM  VapA+  has  also  induced
protection  in  Tlr2−/− mice  and  mice  with  non-functional  TLR4.  Moreover,  spleen  cells  of  vaccinated  mice
augmented  T-bet  expression,  as  well  as  the  production  of  IL-12,  IFN-,  nitric  oxide  and hydrogen  perox-
ide. Notably,  the  population  of  CD4+ T  cells  with  memory  phenotype  signiﬁcantly  increased  in  the  spleens
of vaccinated  mice  challenged  1  or  5  months  after  immunisation.  In  these  animals,  the  spleen  bacterial
burden  was  also  reduced.  When  similar  experimental  procedures  were  performed  in  TLR2  knockout
mice,  an  increase  in  CD4+ T cells  with  memory  phenotype  was  not  observed.  Consequently,  we conclude
that  nasal  vaccination  with  attenuated  Salmonella  expressing  the  R. equi  virulence  factor  VapA  confers
long-lasting  protection  against  experimental  rhodoccocosis  and  that  TLR2  engagement  was  not  crucial
to induce  this  protection  but  may  be required  for a  long-term  immune  response.. Introduction
Rhodococcus equi is a soil organism distributed worldwide that
nfects foals aged 1–6 months and causes severe granulomatous
neumonia [1]. As R. equi survives and reproduces inside host cells,
neumonia caused by this pathogen must be treated with lipophilic
rugs over a prolonged period of time [2]. Currently, no vaccines
re available, although several immunisation strategies have been
ested to prevent rhodococcosis [3].
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andeirantes, 3900, 14040-900 Ribeirão Preto, SP, Brazil. Tel.: +55 1681370617.
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As R. equi harbours an 80–90-kb plasmid, proteins (Vaps)
encoded by this plasmid are considered good candidates for vacci-
nal antigens. VapA is the most investigated immunogen encoded
by this pathogenicity island and has been reported to account
for R. equi virulence [4,5] and elicit speciﬁc immune responses
[6,7]. In this context, our group has previously demonstrated
that oral immunisation with live attenuated Salmonella enter-
ica Typhimurium expressing VapA confers long-term protection
against R. equi. Protection is due to the induction of strong mucosal,
humoral and cell-mediated Th1-immunity, which is appropriately
regulated, as veriﬁed by the proﬁle of cytokines expressed in the
organs of vaccinated mice after bacterial challenge [8,9]. These
promising results have motivated us to advance studies on the
vaccinal conception of VapA.
Studies on the innate immune response to R. equi have shown
that infected macrophages with viable bacteria undergo NFkB
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ranslocation and produce a variety of pro-inﬂammatory media-
ors, including TNF, IL-12, and nitric oxide (NO). This response was
ttributed to a pathway that is strongly dependent on the acti-
ation of Toll-like receptor 2 (TLR2) but not of TLR4. As puriﬁed
apA induces responses that are similar to those triggered by the
hole bacteria, TLR2 activation was attributed to its interaction
ith VapA. These observations prompted us to investigate whether
LR2 accounts for protection conferred by vaccination with VapA.
In the present study, we standardised a new route and regi-
en  of immunisation with the VapA antigen in the context of a
almonella-vectored vaccine and investigated the role that TLR2
lays in the vaccine effect. We  found that nasal vaccination of mice
ith a single dose of VapA-expressing Salmonella confers protec-
ion against R. equi infection via a mechanism that does not depend
n TLR2 activation. Moreover, the vaccination procedure stimu-
ates memory T CD4+ cells and promotes speciﬁc immune response
ecall.
. Materials and methods
.1. Experimental animals
Groups of female mice, 6–8 weeks of age, including BALB/c,
3H/HeJ, C3H/HePAS, Tlr2−/− and wild type (WT) C57BL/6 mice
ﬁve mice per group), were housed under speciﬁc pathogen-free
onditions in the Animal Research Facilities of the Medical School
f Ribeirão Preto-USP. The studies were conducted as required by
he Ethics Committee on Animal Research of the University of São
aulo.
.2. Bacterial strains
The attenuated S. enterica Typhimurium 3987 strains, carrying
ither the VapA antigen (STM VapA+) or the empty vector (control
apA−), were grown and prepared for the immunisation of ani-
als as described by Oliveira et al. [9]. The virulent strain of R. equi
ATCC 33701) was grown and the titre of the challenge inoculum
as calculated as described by Oliveira et al. [8].
.3. Immunisation and challenge protocol
Groups of animals were immunised with a single dose or two
oses of attenuated Salmonella harbouring the VapA antigen via
ntranasal route (1 × 109 CFU, 5 L/animal). As a control, groups
ere inoculated with attenuated Salmonella carrying an empty vec-
or according to the same schedule.
The challenges were conducted using an ATCC virulent, R. equi
train 33701 30 days after the ﬁrst immunisation. In the Balb/c
ecall experiments, the animals were challenged 5 months after
mmunisation. In contrast, in the C57Bl/6 recall experiments, WT
nd Tlr2−/− animals were challenged 120 days after immunisation.
Organs were collected 5 days after challenge for R. equi clearance
valuation and other analyses as described below.
.4. Estimation of bacterial clearance in the organs of infected
ice
Quantiﬁcation of viable R. equi recovered from the spleen and
iver of challenged mice was performed on day 5 post-infection as
eported elsewhere [8]. Brieﬂy, 30 days after the ﬁrst immunisa-
ion procedure with STM VapA+, mice were infected with 4 × 106
FUs (Colony Forming Units) of virulent R. equi via intravenous
oute. Five days after the challenge, spleen and liver were collected
nd aseptically homogenised. To determine the number of CFUs,1 (2013) 4528– 4535 4529
aliquots of 100 L of the homogenates were serially diluted in PBS,
plated onto BHI agar in duplicate, and incubated at 37 ◦C for 36 h.
2.5. Detection of cytokines in spleen homogenates
Spleen homogenate samples were analysed via ELISA for IL-
12p40, INF-, and TNF- using commercially available kits (OptEIA
set; Pharmingen, San Diego, CA, USA). The assays were performed
according to the manufacturer’s recommendations.
2.6. Real time quantitative PCR analysis
Total cellular RNA was  extracted from spleen cell samples using
TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s recommendations. Real time PCR
was  performed as previously described by Oliveira et al. [9] using
primers for GATA-3, T-bet, TLR2, and -actin.
2.7. Flow cytometry analysis
Staining for ﬂow cytometry was  performed on spleen cells iso-
lated from immunised and control mice 30 days post-infection.
After harvesting the spleen cells, 1 × 106 cells were washed with
ice-cold PBS and incubated for 30 min  at 4 ◦C with 0.5 g of anti-
CD16/CD32 mAb  (Fc block, clone 2.4G2, BD Pharmingen, San Diego,
CA). Next, the cells were incubated for over 30 minutes with 5 g of
phycoerythrin-conjugated anti-CD62L, ﬂuorescein isothiocyanate-
conjugated anti-CD44, anti-TLR2, and PECy5-conjugated anti-CD3
(BD Pharmingen, San Diego, CA). Washing steps were performed
with PBS 0.5% BSA and the cells were then submitted for analy-
sis on a Guava ﬂow cytometer (Millipore, Billerica, MA,  USA) using
Guava CytoSoft version 4.2.1 (Millipore, Billerica, MA,  USA).
2.8. Statistical analysis
Statistical analysis (one-way analysis of variance) was per-
formed in conjunction with the Tukey multiple comparison test
using GraphPad Prism version 5.00 (GraphPad Software, San Diego,
CA, USA). The results are presented as the mean and SE. Differences
between groups were considered signiﬁcant at the level of p < 0.05.
3. Results
3.1. Nasal immunisation with STM VapA+ protects mice against
R. equi infection
Our previous studies have demonstrated that oral immunisa-
tion of Balb/c mice with live attenuated S. enterica Typhimurium
(STM) expressing VapA antigen (STM VapA+) is an effective strategy
to induce protection against R. equi infection [8,9]. In the present
study, we performed nasal immunisation of Balb/c mice with a sin-
gle dose or two doses of the STM VapA+. Both procedures resulted
in a signiﬁcant reduction in the R. equi burden in the spleen and liver
of mice challenged 30 days after the ﬁrst immunisation compared
with the organs of animals injected with control VapA− (negative
control) (Fig. 1A and B). Because both immunisation regimens pro-
moted comparable R. equi clearance, the protocol using a single
nasal inoculation of STM VapA+ was elected for subsequent exper-
iments.
To optimise the quantity of the vaccine inoculum, groups of
Balb/c mice were immunised with different doses of STM VapA+
(102–109) and challenged with R. equi 30 days after immunisa-
tion. A signiﬁcant reduction in splenic R. equi burden was  observed
when the inoculum of the VapA+ vaccine strain was at least 107
CFU (Fig. 1C).
4530 S.A. Cardoso et al. / Vaccine 31 (2013) 4528– 4535
Fig. 1. Nasal immunisation with STM VapA+ reduces R. equi burden in infected mice. Balb/c mice were immunised with a single dose or two doses of attenuated Salmonella
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arrying empty vector was used as a negative control (Control). Data represent the 
.2. Nasal immunisation with STM VapA+ induces Th1 immunity
To evaluate whether the protection conferred with the novel
accination procedure was associated with the development of Th1
mmunity as previously veriﬁed for oral vaccination, we  assessed
he level of some mediators in the spleens of mice immunised with
he STM VapA+ strain and challenged the animals with R. equi. IL-12
Fig. 2A), nitric oxide (Fig. 2B) and hydrogen peroxide levels (Fig. 2C)
ere signiﬁcantly higher in the spleen tissue of VapA+-immunised
ice, while the levels of TNF- remained lower (Fig. 2D).
To better characterise the immune response induced by the
accination procedure, we determined the mRNA levels for the
ranscription factors GATA-3 and T-bet 30 days after immunisa-
ion. Compared with the negative controls, i.e., mice injected with
ontrol VapA− or PBS, mice immunised with STM VapA+ displayed
igher levels of T-bet mRNA (Fig. 2E) and lower levels of GATA-3
RNA (Fig. 2F). Similar analyses were performed 5 days after chal-
enging, and no difference in the levels of T-bet mRNA was observed
mong all groups (Fig. 2E). GATA-3 mRNA levels remained lower in
accinated/challenged animals (Fig. 2F).
.3. Nasal immunisation with STM VapA+ induces memory T cells
nd immune response recall
To evaluate the induction of T cells with memory phenotype
ia nasal vaccination with STM VapA+, we have assessed the fre-
uency of cells co-expressing CD3, CD62L and CD44 (high) markers,
hich characterise T cells with memory phenotype, 30 days after
mmunisation. This population, according to the ﬂow cytometric
nalysis, was larger in the spleens of vaccinated mice compared
ith the control groups (Fig. 3A). We  also investigated whether the on day 5 after infection, and R. equi burden was evaluated in the spleen (A) and
 immunised with a single dose of various vaccine inoculum. Attenuated Salmonella
 ± SE, n = 5 animals. #p < 0.05.
expansion of the population of cells was  associated with immune
response recall. Accordingly, Balb/c mice were immunised and
challenged 5 months later. Next, spleen and liver were collected
for analysis 5 days after challenge. Our results demonstrate a sig-
niﬁcant decrease in R. equi burden in the group immunised with
STM VapA+ (Fig. 3B and C).
3.4. TLR-2 expression is upregulated after immunisation and
downregulated after challenge
It is well established that VapA can activate Toll-like recep-
tor 2; this interaction is considered a major mechanism involved
in triggering speciﬁc immune responses to R. equi. Therefore, the
expression levels of TLR2 in the spleen cells of mice vaccinated
with STM VapA+ were evaluated via real time PCR (Fig. 4A) and
ﬂow cytometry (Fig. 4B), which was  compared with the expres-
sion levels in the cells of mice injected with the controls VapA−
or PBS. Thirty days after immunisation, mice spleen cells displayed
an increase in TLR2 expression levels, as demonstrated by elevated
mRNA (Fig. 4A) and protein levels (Fig. 4B). Five days after challenge
with R. equi, murine spleen cells displayed reduced TLR2 expression
levels similar to that detected in the negative control group.
3.5. Protection against R. equi conferred by STM VapA+ is not
dependent on TLR2
We  further investigated the role that TLR2 plays in the VapA+
vaccine-induced protection against R. equi infection. Accordingly,
groups of TLR2 knockout mice (C57Bl/6 Tlr2−/−) or wild type mice
(WT) were treated with the standard vaccination and challenge
protocols. As expected, among all WT  vaccinated mice, R. equi
S.A. Cardoso et al. / Vaccine 31 (2013) 4528– 4535 4531
Fig. 2. Nasal immunisation with STM VapA+ induces Th1-immunity. Balb/c mice were immunised with a single dose of STM VapA+ and the levels of IL-12 (A), nitric oxide
(B),  hydrogen peroxide (C) and TNF- (D) in the spleen were evaluated. The relative mRNA expression levels of T-bet (E) and GATA-3 (F) were also analysed. Attenuated
Salmonella carrying empty vector was used as negative control. Data represent the mean ± SE, n = 5 animals. #p < 0.05.
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vurden in the spleen (Fig. 5A) and liver (Fig. 5B) was  less than that
etected in the organs of negative control mice injected with the
ontrols VapA− or PBS. Nonetheless, similar results were obtained
ith the Tlr2−/− group, thereby indicating that TLR2 is not essential
or the protection conferred by our VapA+ method of vaccination
sing attenuated Salmonella.  This indication was reinforced by the
act that similar levels of IL-12 (Fig. 5C), IFN- (Fig. 5D) and TNF
Fig. 5E) were detected in the spleen tissue of the Tlr2−/− and WT
nimals. Additionally, these results show that STM VapA+ vaccina-
ion of C57BL/6 and Balb/c mice is able to confer protection against
. equi infection and induces Th1 immune response as denoted by
ncreased production of IL-12 and IFN-.
Similar immunisation and challenges were performed in mice
ith non-functional TLR4 (C3H/HeJ). In these animals, R. equi clear-
nce was comparable to that observed in the spleen (Fig. 5F)
nd liver (Fig. 5G) of vaccinated mice expressing functional TLR4
C3H/HePAS). This result indicates that the protection conferred by
accination with the STM VapA+ strain is also independent of TLR4.3.6. High frequency of memory phenotype CD4 T cells is
maintained in the absence of TLR2
To understand the function of TLR2 in the nasal immunisation-
mediated response, we  investigated whether the emergence of
memory T cells induced by vaccination could be affected by the
absence of TLR2. The frequency of CD4+ or CD8+ T cells express-
ing CD44high/CD62L was  measured in the spleen of WT  and Tlr2−/−
mice 30 days after immunisation. As shown in Fig. 6A, vaccination
led to an increased cell population with a CD4+CD62L+CD44+high
phenotype. Notably, this increase was similar for WT  and Tlr2−/−
mice. In contrast, the population of CD8+CD62L+CD44+high cells was
elevated only in the spleens of vaccinated WT  mice, thereby indi-
cating that vaccination had no effect on the frequency of these cells
−/−in Tlr2 animals (Fig. 6B).
Finally, we assessed the frequency of T cells with memory phe-
notype in challenged animals (120 days post-immunisation). In this
particular case, the CD4+CD62L+CD44+high population remained
4532 S.A. Cardoso et al. / Vaccine 31 (2013) 4528– 4535
Fig. 3. Nasal immunisation with STM VapA+ increases the splenic population of T cells with memory phenotype and the recall of immune response. Vaccinated Balb/c mice
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as  challenged 5 months after immunisation and evaluated in terms of spleen (B)
egative control. Data represent the mean ± SE, n = 5 animals. #p < 0.05.
levated in WT,  but not in Tlr2−/− mice (Fig. 6C). Regarding the
D8+CD62L+CD44+high cells, no noticeable difference was detected
mong all groups of animals (Fig. 6D).
. Discussion
Various strategies have been proposed for the development of a
afe and effective vaccine against rhodococcosis. For instance, the
assive immunisation with hyperimmune plasma [10], vaccination
rocedures with inactivated R. equi strains [11], VapA DNA vaccine
12] and, more recently, attenuated R. equi vaccine [13] have been
eported. However, none of these approaches have provided an efﬁ-
ient method to control the disease. Among the different strategies
f vaccination for intracellular pathogens, a promising approach
ay  be the use of live oral vaccines. In this context, our group has
ig. 4. Nasal vaccination with STM VapA+ enhances TLR2+ expression levels in spleen c
RNA  in the spleen cells of vaccinated Balb/c mice either unchallenged or challenged o
ells  positive for TLR2 staining as detected via ﬂow cytometry. Attenuated Salmonella h
ormalised on the basis of predetermined -actin levels. Data represent the mean ± SEMncy of CD3 /CD62L /CD44 cells (A) was analysed. A second group of Balb/c mice
ver (C) R. equi burden. Attenuated Salmonella carrying empty vector was used as a
demonstrated that oral immunisation with an attenuated S. enterica
Typhimurium strain expressing the VapA protein induces protec-
tion against experimental rhodococcosis in mice [8]. More recently,
we have demonstrated that the oral immunisation protocol induces
a strong and speciﬁc humoral and cell-mediated Th1-immunity
against the heterologous antigen, with an appropriate regulatory
response and a long-term protection against R. equi infection [9]. In
the present work, we  report that nasal delivery is an effective route
for immunisation, which confers protection with a single dose of
the vaccine. We  have also veriﬁed that nasal vaccination induces
a Th1 immune response, which is as protective and speciﬁc as the
oral immunisation [9].Nasal route has been proposed as an alternative route for vacci-
nation due to ease of the process of immunisation and the presence
of nasopharynx-associated lymphoid tissue (NALT). As with the
Peyer’s patches, NALT accomplishes the requirements to induce
ells, which is reverted by R. equi challenge. The relative expression levels of TLR2
r with R. equi is shown in panel A. Panel B shows the relative frequency of spleen
arbouring empty vector was used as a negative control. In (A), cDNA content was
 (n = 5 animals). #p < 0.01. In (B), data represent the mean ± SE. #p < 0.05.
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Fig. 5. Protection induced by nasal vaccination with STM VapA+ is independent of TLR2 activation. WT  and Tlr2−/− C57BL/6 mice were challenged with R. equi 30 days after
vaccination with STM VapA+. Five days after challenge, R. equi burden in the spleen (A) and liver (B) was evaluated. The spleen tissue was  also analysed for the levels of
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nd  liver (G) samples. Attenuated Salmonella carrying empty vector was used as a n
nd regulate a protective immune response, which involves M cells,
PCs, T cells and B cells [14]. Nonetheless, NALT is characterised as
 Th0 environment, which can be reverted to either Th1 or Th2
rone ambiance [15]. Although the oral administration is a nat-
ral route for Salmonella-based vaccines, the intranasal delivery with C3H/HePAS and C3H/HeJ mice; R. equi burden was assessed in the spleen (F)
e control. The bars represent the mean ± SEM (n = 5 animals). #p < 0.05.
allows for the immunogen to reach the same organs, including
the lungs and Peyer’s patches and, as a consequence, can induce
serologic and proliferative responses [16]. Currently, Kim et al. [17]
have demonstrated that attenuated Salmonella Typhimurium is an
efﬁcient carrier of heterologous antigens, which is able to involve
4534 S.A. Cardoso et al. / Vaccine 31 (2013) 4528– 4535
Fig. 6. Nasal immunisation with STM VapA+ induces increased frequency and recall of CD4+ T cells with memory phenotype via a TLR2-dependent mechanism. Immunised
WT  and Tlr2−/− C57BL/6 mice were challenged with R. equi 30 days (panels A and B) or 120 days (panels C and D) after vaccination. The frequencies of CD4+/CD62L+/CD44high
(A and C) and CD8+/CD62L+/CD44high cells (B and D) were assessed via ﬂow cytometry in spleen samples. Attenuated Salmonella carrying empty vector was used as a negative
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 cells in nasopharynx and tracheobronchial lymphoid tissue and
nduce local and systemic-speciﬁc immune responses. Such ﬁnd-
ngs have motivated several groups to develop Salmonella-vectored
accines for administered via nasal route in mice [18,19] and mares
20].
Darrah and co-workers [21] have demonstrated that the
ipoprotein VapA activates macrophage TLR2, a receptor that is a
ajor mediator of the innate response to R. equi. Therefore, along
ith the knowledge that TLR2 activation favours the differentia-
ion of Th1 cells, it is likely that this receptor could play a role
n the protection conferred by Salmonella-expressing VapA used
erein. This idea was reinforced with the fact that vaccination ele-
ated TLR2 expression levels on murine macrophages. However,
he high TLR2 expression levels were not maintained when the
mmunised mice were challenged with R. equi. With regards to
his ﬁndings, they might be related to (i) a supposed TLR2 inter-
alisation, which accompanies the internalisation of R. equi or (ii)
riggering a signal via TLR2 activation, thereby inducing a negative
eedback mechanism able to control inﬂammation after challenge.
he latter assumption is supported by the observation that TNF-
evels also decreased after R. equi challenge.
Activation of TLRs directly modulates T cell biology [22–24]. In
his context, alteration of TLR2 expression levels by these cells could
ffect vaccine efﬁciency and the frequency of T cell populations.
urprisingly, the results of protection with the STM VapA+ vaccine
ere somewhat similar for both the WT  and the Tlr2−/− animals,
s shown by a similar reduction in R. equi burden in the spleen and
iver. Furthermore, the population of CD4+ T cells with memory
henotype was similarly expanded in Tlr2−/− and WT  vaccinated
ice. The frequency of CD8+ T cells with memory phenotype; how-ver, was only greater in WT  mice after vaccination. These results
re supported by the study of Cottalorda and co-workers [25],
hich demonstrated that TLR2 plays a critical role in the gener-
tion of memory CD8+ T cells. Our results indicate that CD4+ T cellsplay a major role in R. equi immunity. This is in agreement with
the fact that activated CD4+ T cells express TLR3 and TLR9 but not
TLR2 and TLR4 [24]. Following vaccination, activation of CD4+ T
cells occurs independent of their direct interaction with VapA or
Salmonella components.
Our results do not exclude the possibility that TLR2 might par-
ticipate in the protective response against R. equi induced by STM
VapA+. A closer examination of our results reveals that vaccinated
WT mice displayed a reduced bacterial burden of almost 3 logs,
while the vaccinated Tlr2−/− mice displayed a reduced burden of
approximately 1.5 logs. Thus, the VapA antigen, in the context of
the Salmonella cell, is able to induce a protective immune response
via a pathway that is independent of TLR2 activation. Neverthe-
less, TLR2 seems to act synergistically to mount a strong protective
response against R. equi.
The exact mechanism by which the VapA+ antigen is presented
by the attenuated Salmonella remains unclear. S. enterica serovars
survive inside the host cells. Although attenuated strains were
shown to be unable to cause disease, they retain the ability to
colonise the host tissue and trigger certain signals in the context of
the host cells. Likewise, R. equi is an intracellular pathogen and nat-
ural infection should be mimicked via vaccination with STM VapA+,
which has the advantage of providing better conditions for presen-
tation of the VapA antigen. Such presentation seems to be crucial,
as VapA is highly associated with R. equi virulence and thus is
extensively described as a good antigen for vaccination. Currently,
many strategies have been proposed based on the immunity devel-
oped against VapA, but only few of strategies were considered to
have potential for vaccine application. The results presented herein
suggest that the 3987 attenuated strain of Salmonella is an efﬁ-
cient carrier for oral or nasal immunisation with VapA. The vaccine
stimulates antigen-speciﬁc CD4+ T cells without the participation
of TLR2 and leads to a proﬁle of immune response that confers
resistance to the R. equi infection. Most importantly, the efﬁcient
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